Current therapeutic paradigms for ESCC demonstrate that immune checkpoint inhibitor (ICI)-chemotherapy combinations now constitute first-line standard care for advanced-stage disease (35), particularly in PD-L1-positive populations as evidenced by survival improvements in pivotal trials (36). The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.